胰岛素对应激复发性炎症性肠病的保护作用
Yao Du1, Kanta Kusama2, Koki Hama2
1School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8501, Japan.
International journal of molecular sciences
|March 13, 2024
概括
胰岛素补充剂通过减少肠道炎症和恢复微生物平衡,有效地对抗炎症性肠病 (IBD). 这种益生菌提高了肠道免疫力,并减轻了 stress-recurrent IBD 模型中的 endoplasmic reticulum 压力.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 炎症性肠病 (IBD) 是一种与肠道微生物群不平衡相关的慢性消化道疾病.
- 益生菌纤维的胰岛素因其抗炎性质和维持肠道平衡的能力而闻名.
研究的目的:
- 在压力复发性IBD模型中研究胰岛素在增强肠道免疫力和减少炎症方面的治疗潜力.
- 探索胰岛素对促炎性细胞因子,MUC2表达,血清炎症标记物,短链脂肪酸 (SCFA) 和内质网膜 (ER) 压力的影响.
主要方法:
- 利用共同培养的肠表皮模型和压力复发IBD小鼠模型.
- 评估了细胞因子表达的变化 (CXCL8/IL8,TNFA,Il6),MUC2,血清标记物 (IL-6,CALP),SCFA和ER压力标记物 (CHOP,BiP).
主要成果:
- 胰岛素显著降低了促炎性细胞因子表达,并在肠道上皮细胞中增加了MUC2表达.
- 胰岛素摄入预防了体内IBD症状,降低了血清炎症标志物和结肠Il6表达.
- 胰岛素增加了SCFA的产生,并减少了眼膜中的ER压力标志物.
结论:
- 胰岛素通过调节微生物群,减少炎症和减轻ER压力来改善压力复发性IBD.
- 胰岛素作为一种饮食干预来改善压力复发性IBD的治疗潜力.
关键词:
压力ERER压力ERER压力IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD在SCFAs中,SCFAs是最重要的.细胞因子 细胞因子在这种情况下,胰岛素和胰岛素是不同的.一个叫做mucincin的孩子.压力就是压力,压力就是压力.更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Irritable Bowel Syndrome I: Introduction
273
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
273
Drugs for Treatment of Diarrhea-Predominant IBS
167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167
Irritable Bowel Syndrome III: Medical and Nursing Management
202
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
202
Drugs for Treatment of Constipation-Predominant IBS
162
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


